Abstract What is known and objective Recent studies prove that epidermal growth factor receptor (EGFR) inhibitors combined with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are more effective than EGFR TKI monotherapy for treatment of EGFR‐mutated advanced non‐small‐cell lung cancer (NSCLC); however, the adverse effects associated with this treatment require further investigation. We report a case of fingerprint loss secondary to combination therapy using osimertinib (an EGFR TKI that targets mutated EGFR kinases) and anlotinib (a TKI that acts on multiple targets including mutated VEGFR kinases). Case summary A 55‐year‐old man with stage IV lung adenocarcinoma and an EGFR L858R mutation received a 5‐month course of platinum‐based chemotherapy and icotinib. This regimen was subsequently switched to osimertinib plus anlotinib to achieve a better tumour response. This therapy led to fingerprint loss, which recovered following discontinuation of anlotinib treatment but subsequently recurred. What is new and conclusion To our knowledge, this is the first report that describes fingerprint loss during combination therapy using osimertinib and anlotinib.
展开▼
